Sensei Biotherapeutics Inc (SNSE)
$0.49
Performance
- $0.48$0.50$0.49
1.84%
Downside
Day's Volatility :4.18%
Upside
2.39%
- $0.38$1.94$0.49
21.63%
Downside
52 Weeks Volatility :80.21%
Upside
74.74%
Returns
| Period | Sensei Biotherapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -3.89% | 7.5% | 0.0% |
6 Months | -39.6% | 6.9% | 0.0% |
1 Year | -15.77% | 20.9% | 0.0% |
3 Years | -93.91% | 21.0% | -21.1% |
Highlights
Market Capitalization | 14.0M |
Book Value | $2.08 |
Earnings Per Share (EPS) | -1.18 |
Wall Street Target Price | 4.25 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -27.03% |
Return On Equity TTM | -45.17% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -31.0M |
Diluted Eps TTM | -1.18 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.11 |
EPS Estimate Next Year | -1.12 |
EPS Estimate Current Quarter | -0.29 |
EPS Estimate Next Quarter | -0.28 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 767.35%
Technicals Summary
Sell
Neutral
Buy
Sensei Biotherapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Sensei Biotherapeutics Inc | -0.32% | -39.6% | -15.77% | -93.91% | -96.84% |
 Regeneron Pharmaceuticals, Inc. | -10.06% | 10.55% | 30.05% | 89.27% | 274.48% |
 Novo Nordisk A/s | -12.62% | -6.24% | 35.65% | 145.66% | 372.59% |
 Alnylam Pharmaceuticals, Inc. | 8.37% | 82.34% | 59.06% | 41.03% | 258.58% |
 Vertex Pharmaceuticals Incorporated | -2.23% | 13.76% | 34.75% | 162.16% | 172.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Sensei Biotherapeutics Inc | NA | NA | NA | -1.11 | -0.45 | -0.27 | NA | 2.08 |
Regeneron Pharmaceuticals, Inc. | 27.85 | 27.85 | 1.43 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.39 | 40.39 | 1.82 | 3.45 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Sensei Biotherapeutics Inc | Buy | $14.0M | -96.84% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $115.9B | 274.48% | 27.85 | 32.04% |
Novo Nordisk A/s | Buy | $531.4B | 372.59% | 40.39 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $35.3B | 258.58% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.0B | 172.77% | 32.84 | -4.74% |
Insights on Sensei Biotherapeutics Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.1% return, outperforming this stock by 74.9%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.7% return, outperforming this stock by 137.0%
Institutional Holdings
Ikarian Capital, LLC
2.58%Vanguard Group Inc
2.46%Renaissance Technologies Corp
0.89%BOOTHBAY FUND MANAGEMENT, LLC
0.69%Geode Capital Management, LLC
0.65%Bridgeway Capital Management, LLC
0.31%
Company Information
sensei biotherapeutics is an innovator in the field of next-generation cancer immunotherapies. sensei has pioneered a proprietary immuno-oncology technology platform, called spirit, to aid the immune system in the detection and elimination of cancer. the presence of subtle differences in antigen expression between cancer and normal is key to this process the spirit platform overcomes disabled immune recognition caused by cancer. the immune system has evolved to protect its host from foreign pathogens, effectively distinguishing healthy ‘self’ tissues from ‘non-self’. cancer is a unique challenge to the immune system. it arises from ‘self’ making immune recognition challenging, yet it is known to be altered. immune recognition of the subtle differences between ‘self’ and ‘non-self’ is key to effective cancer immunotherapy. headquartered in gaithersburg, md, sensei has built a unique and proprietary approach in-house and in collaboration with key academic collaborators at brown universit
Organization | Sensei Biotherapeutics Inc |
Employees | 28 |
CEO | Mr. John K. Celebi M.B.A. |
Industry | Services |
